HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
POLD2
DNA polymerase delta 2, accessory subunit
Chromosome 7 · 7p13
NCBI Gene: 5425Ensembl: ENSG00000106628HGNC: HGNC:9176UniProt: A0A087WWF6
93PubMed Papers
20Diseases
7Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
DNA Repair
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
zeta DNA polymerase complexprotein bindingDNA biosynthetic processnucleoplasmacute myeloid leukemiaacute lymphoblastic leukemianon-small cell lung carcinomachronic lymphocytic leukemia
✦AI Summary

POLD2 (DNA polymerase delta 2, accessory subunit) is an essential component of both DNA polymerase delta and zeta complexes that plays critical roles in DNA replication, repair, and genomic stability 1. As an accessory subunit, POLD2 contributes to high-fidelity lagging strand synthesis and DNA repair processes, with its depletion destabilizing the entire polymerase delta complex and leading to degradation of POLD1 and POLD3 subunits 2. The protein facilitates translesion synthesis by mediating interactions between replicative and repair polymerases, exemplified by its interaction with DNA polymerase η through specific amino acid motifs that are crucial for DNA damage tolerance and UV-induced lesion bypass 1. POLD2 also promotes alternative nonhomologous end-joining pathways and chr7 rearrangements at double-strand breaks 2. Clinically, POLD2 expression is significantly upregulated across multiple cancer types and correlates with poor prognosis 3. High POLD2 expression is associated with advanced tumor stages, shorter survival, and treatment resistance in various malignancies including glioblastoma, lung adenocarcinoma, ovarian carcinoma, and multiple myeloma 4567. In lung adenocarcinoma, POLD2 promotes cell cycle progression through MYC pathway activation, leading to increased malignancy and poor outcomes 5. These findings establish POLD2 as both a crucial DNA repair protein and potential therapeutic target in cancer treatment.

Sources cited
1
POLD2 is an essential component of DNA polymerase complexes and mediates interaction with translesion synthesis polymerases
PMID: 25662213
2
POLD2 depletion destabilizes the polymerase delta complex and promotes chromosomal rearrangements
PMID: 33077594
3
POLD2 is overexpressed in most tumors and correlates with poor prognosis across cancer types
PMID: 36081989
4
High POLD2 expression correlates with poor survival in glioblastoma and contributes to treatment resistance
PMID: 31954770
5
POLD2 activates cell cycle progression through MYC pathway in lung adenocarcinoma
PMID: 40095310
6
POLD2 expression correlates with histology, stage and poor outcome in ovarian carcinomas
PMID: 21079801
7
POLD2 expression is negatively associated with overall survival in multiple myeloma patients treated with ASCT
PMID: 36861411
Disease Associationsⓘ20
acute myeloid leukemiaOpen Targets
0.59Moderate
acute lymphoblastic leukemiaOpen Targets
0.59Moderate
non-small cell lung carcinomaOpen Targets
0.59Moderate
chronic lymphocytic leukemiaOpen Targets
0.59Moderate
pancreatic carcinomaOpen Targets
0.58Moderate
neoplasmOpen Targets
0.57Moderate
breast carcinomaOpen Targets
0.54Moderate
ovarian carcinomaOpen Targets
0.54Moderate
breast cancerOpen Targets
0.53Moderate
ovarian cancerOpen Targets
0.52Moderate
myelodysplastic syndromeOpen Targets
0.51Moderate
leptomeningeal metastasisOpen Targets
0.45Moderate
cancerOpen Targets
0.43Moderate
leukemiaOpen Targets
0.42Moderate
lymphomaOpen Targets
0.42Moderate
lung cancerOpen Targets
0.42Moderate
nasopharyngeal carcinomaOpen Targets
0.42Moderate
urinary bladder cancerOpen Targets
0.41Moderate
diffuse large B-cell lymphomaOpen Targets
0.41Moderate
Malignant Pancreatic NeoplasmOpen Targets
0.40Moderate
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets7
ASPACYTARABINEPhase II
DNA polymerase (alpha/delta/epsilon) inhibitor
acute myeloid leukemia by FAB classification
CLOFARABINEApproved
DNA polymerase (alpha/delta/epsilon) inhibitor
acute lymphoblastic leukemia
CYTARABINEApproved
DNA polymerase (alpha/delta/epsilon) inhibitor
acute lymphoblastic leukemia
FLUDARABINE PHOSPHATEApproved
DNA polymerase (alpha/delta/epsilon) inhibitor
GEMCITABINEApproved
DNA polymerase (alpha/delta/epsilon) inhibitor
GEMCITABINE HYDROCHLORIDEApproved
DNA polymerase (alpha/delta/epsilon) inhibitor
breast carcinoma
TROXACITABINEPhase II
DNA polymerase (alpha/delta/epsilon) inhibitor
Related Genes
RFC5Protein interaction100%TOP3AProtein interaction100%KCTD13Protein interaction99%KCTD10Protein interaction98%POLHProtein interaction94%MAD2L2Protein interaction93%
Tissue Expression6 tissues
Liver
100%
Heart
80%
Ovary
61%
Brain
45%
Bone Marrow
45%
Lung
40%
Gene Interaction Network
Click a node to explore
POLD2RFC5TOP3AKCTD13KCTD10POLHMAD2L2
PROTEIN STRUCTURE
Preparing viewer…
PDB3E0J · 3.00 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.93LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.69 [0.52–0.93]
RankingsWhere POLD2 stands among ~20K protein-coding genes
  • #5,159of 20,598
    Most Researched93
  • #302of 1,025
    FDA-Approved Drug Targets5
  • #8,583of 17,882
    Most Constrained (LOEUF)0.93
Genes detectedPOLD2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
PMID: 36861411
Haematologica · 2023
1.00
2
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and outcome in ovarian carcinomas.
PMID: 21079801
PLoS One · 2010
0.90
3
ShRNA-based POLD2 expression knockdown sensitizes glioblastoma to DNA-Damaging therapeutics.
PMID: 31954770
Cancer Lett · 2020
0.80
4
Cloning of the cDNAs for the small subunits of bovine and human DNA polymerase delta and chromosomal location of the human gene (POLD2).
PMID: 8530069
Genomics · 1995
0.70
5
An integrative analysis revealing POLD2 as a tumor suppressive immune protein and prognostic biomarker in pan-cancer.
PMID: 36081989
Front Genet · 2022
0.60